These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 22563432)

  • 1. Effects of PPARs agonists on cardiac metabolism in littermate and cardiomyocyte-specific PPAR-γ-knockout (CM-PGKO) mice.
    Barbieri M; Di Filippo C; Esposito A; Marfella R; Rizzo MR; D'Amico M; Ferraraccio F; Di Ronza C; Duan SZ; Mortensen RM; Rossi F; Paolisso G
    PLoS One; 2012; 7(4):e35999. PubMed ID: 22563432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice.
    Duan SZ; Ivashchenko CY; Russell MW; Milstone DS; Mortensen RM
    Circ Res; 2005 Aug; 97(4):372-9. PubMed ID: 16051889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved insulin sensitivity after treatment with PPARγ and PPARα ligands is mediated by genetically modulated transcripts.
    Rasouli N; Kern PA; Elbein SC; Sharma NK; Das SK
    Pharmacogenet Genomics; 2012 Jul; 22(7):484-97. PubMed ID: 22437669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
    Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PPAR agonist-induced reduction of Mcp1 in atherosclerotic plaques of obese, insulin-resistant mice depends on adiponectin-induced Irak3 expression.
    Hulsmans M; Geeraert B; Arnould T; Tsatsanis C; Holvoet P
    PLoS One; 2013; 8(4):e62253. PubMed ID: 23620818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxisome proliferator-activated receptor-γ in capillary endothelia promotes fatty acid uptake by heart during long-term fasting.
    Goto K; Iso T; Hanaoka H; Yamaguchi A; Suga T; Hattori A; Irie Y; Shinagawa Y; Matsui H; Syamsunarno MR; Matsui M; Haque A; Arai M; Kunimoto F; Yokoyama T; Endo K; Gonzalez FJ; Kurabayashi M
    J Am Heart Assoc; 2013 Jan; 2(1):e004861. PubMed ID: 23525438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LT175 is a novel PPARα/γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties.
    Gilardi F; Giudici M; Mitro N; Maschi O; Guerrini U; Rando G; Maggi A; Cermenati G; Laghezza A; Loiodice F; Pochetti G; Lavecchia A; Caruso D; De Fabiani E; Bamberg K; Crestani M
    J Biol Chem; 2014 Mar; 289(10):6908-6920. PubMed ID: 24451380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of DSP-8658, a novel selective peroxisome proliferator-activated receptors a/γ modulator, on adipogenesis and glucose metabolism in diabetic obese mice.
    Goto T; Nakayama R; Yamanaka M; Takata M; Takazawa T; Watanabe K; Maruta K; Nagata R; Nagamine J; Tsuchida A; Kato H
    Exp Clin Endocrinol Diabetes; 2015 Sep; 123(8):492-9. PubMed ID: 26011171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptor (PPAR)-gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels.
    Aleshin S; Grabeklis S; Hanck T; Sergeeva M; Reiser G
    Mol Pharmacol; 2009 Aug; 76(2):414-24. PubMed ID: 19483106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation Effect of Peroxisome Proliferator-Activated Receptor Agonists on Lipid Droplet Proteins in Liver.
    Zhu YX; Zhang ML; Zhong Y; Wang C; Jia WP
    J Diabetes Res; 2016; 2016():8315454. PubMed ID: 26770990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel fatty acid mimetic with pan-PPAR partial agonist activity inhibits diet-induced obesity and metabolic dysfunction-associated steatotic liver disease.
    Sahin C; Melanson JR; Le Billan F; Magomedova L; Ferreira TAM; Oliveira AS; Pollock-Tahari E; Saikali MF; Cash SB; Woo M; Romeiro LAS; Cummins CL
    Mol Metab; 2024 Jul; 85():101958. PubMed ID: 38763495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM; Schiffrin EL
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex dimorphic actions of rosiglitazone in generalised peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-deficient mice.
    Duan SZ; Usher MG; Foley EL; Milstone DS; Brosius FC; Mortensen RM
    Diabetologia; 2010 Jul; 53(7):1493-505. PubMed ID: 20401461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis.
    Caglayan E; Stauber B; Collins AR; Lyon CJ; Yin F; Liu J; Rosenkranz S; Erdmann E; Peterson LE; Ross RS; Tangirala RK; Hsueh WA
    Diabetes; 2008 Sep; 57(9):2470-9. PubMed ID: 18511847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.
    Rogue A; Anthérieu S; Vluggens A; Umbdenstock T; Claude N; de la Moureyre-Spire C; Weaver RJ; Guillouzo A
    Toxicol Appl Pharmacol; 2014 Apr; 276(1):73-81. PubMed ID: 24534255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
    Hennuyer N; Tailleux A; Torpier G; Mezdour H; Fruchart JC; Staels B; Fiévet C
    Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1897-902. PubMed ID: 15994444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of peroxisome proliferator activated receptors (PPAR)-γ and -α agonists on cochlear protection from oxidative stress.
    Sekulic-Jablanovic M; Petkovic V; Wright MB; Kucharava K; Huerzeler N; Levano S; Brand Y; Leitmeyer K; Glutz A; Bausch A; Bodmer D
    PLoS One; 2017; 12(11):e0188596. PubMed ID: 29182629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peroxisome proliferator-activated receptor γ decouples fatty acid uptake from lipid inhibition of insulin signaling in skeletal muscle.
    Hu S; Yao J; Howe AA; Menke BM; Sivitz WI; Spector AA; Norris AW
    Mol Endocrinol; 2012 Jun; 26(6):977-88. PubMed ID: 22474127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A PPARs cross-talk concertedly commits C6 glioma cells to oligodendrocytes and induces enzymes involved in myelin synthesis.
    Leisewitz AV; Urrutia CR; Martinez GR; Loyola G; Bronfman M
    J Cell Physiol; 2008 Nov; 217(2):367-76. PubMed ID: 18543250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oleanolic acid induces a dual agonist action on PPARγ/α and GLUT4 translocation: A pentacyclic triterpene for dyslipidemia and type 2 diabetes.
    Loza-Rodríguez H; Estrada-Soto S; Alarcón-Aguilar FJ; Huang F; Aquino-Jarquín G; Fortis-Barrera Á; Giacoman-Martínez A; Almanza-Pérez JC
    Eur J Pharmacol; 2020 Sep; 883():173252. PubMed ID: 32534078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.